Evidence map›Paper›PMID 39212757›Full record

ArticleDiscover oncology2024

Construction and analysis of a lysosome-dependent cell death score-based prediction model for non-small cell lung cancer.

Jiangping Fu, Yaohua Chen, Jie Li, Ming Tan, Rui Lin, Jiang Wang, Guirong Wu, Yao Rao, Fudao Wu, Youshu Gao and 3 more

Abstract read
In one paragraph

Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. The role of lysosome-dependent cell death in cancer.Apoptosis : an international journal on programmed cell death · 2026
    Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jiangping Fu *Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China.
Yaohua Chen *Department of General Respiratory, Dazhou Central Hospital, Dazhou, Sichuan, China.
Jie Li *Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, Sichuan, China.
Ming Tan *Department of Otolaryngology-Head and Neck Surgery, The Central Hospital of Jingmen, Jingmen, China.
Rui LinDepartment of Oncology, Dazhou Central Hospital, Dazhou, Sichuan, China.
Jiang WangDepartment of Oncology, Dazhou Central Hospital, Dazhou, Sichuan, China.
Guirong WuDepartment of Oncology, Dazhou Central Hospital, Dazhou, Sichuan, China.
Yao RaoDepartment of General Respiratory, Dazhou Central Hospital, Dazhou, Sichuan, China.
Fudao WuDepartment of Oncology, Dazhou Central Hospital, Dazhou, Sichuan, China.
Youshu GaoDepartment of Ultrasound Imaging, Dazhou Central Hospital, Dazhou, Sichuan, China.
Maoshu BaiDepartment of Oncology, Dazhou Second People's Hospital, Dazhou Integrated Traditional Chinese Medicine and Western Medicine Hospital, Dazhou, Sichuan, China.
Pingfei WangDepartment of General Respiratory, Dazhou Central Hospital, Dazhou, Sichuan, China. 956565257@qq.com.
Fang WuDepartment of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China. wufang@gxmu.edu.cn.

Funding

the Scientific Research Fund of Technology Bureau in Dazhou 22ZDYF0020
6 · The paper itself

Abstract

backgroundNon-small cell lung cancer (NSCLC) is the most common type of tumor globally and the leading cause of cancer-related deaths. Although treatment strategies such as immune checkpoint inhibitors and chemotherapy have advanced, the heterogeneity among NSCLC patients results in significant variability in treatment outcomes. Studies have shown that certain patients respond poorly to immune checkpoint inhibitors, indicating that treatment response is closely related to multiple factors. Therefore, it is necessary to develop predictive models to stratify patients based on gene expression and clinical characteristics, aiming for precision therapy.

objectiveThis study aims to construct a stratified prognostic model for NSCLC patients based on lysosome-dependent cell death (LDCD) scoring by integrating single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing data. By analyzing the immune-related characteristics of high-risk and low-risk groups, we further explored the impact of cell death patterns on lung cancer and identified potential therapeutic targets.

methodsThis study obtained single-cell RNA sequencing data and gene expression data of NSCLC patients and normal lung tissues from the GEO and TCGA databases. We used R packages such as Seurat and CellChat for data preprocessing and analysis, and performed dimensionality reduction and visualization through Principal Component Analysis (PCA) and UMAP algorithms. LASSO regression analysis was used to construct the predictive model, followed by cross-validation and ROC curve analysis. The model's effectiveness was validated through survival analysis and immune microenvironment analysis.

resultsThe study showed a significant increase in the proportion of monocytes in NSCLC tissues, suggesting their important role in cancer progression. Cell communication analysis indicated that macrophages, smooth muscle cells, and myeloid cells exhibit strong intercellular communication during cancer progression. Using the constructed prognostic model based on 12 LDCD-related genes, we found significant differences in overall survival and immune microenvironment between the high-risk and low-risk groups.

Indexed as

Lysosome-dependent cell deathNon-small cell lung cancerSingle-cell

Identifiers

PMID39212757
PMCPMC11364741

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.